Patients

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

HM
Hua MedicineChina - Shanghai
2 programs
2
EmpagliflozinPhase 1Small Molecule1 trial
SitagliptinPhase 1Small Molecule1 trial
Active Trials
NCT03790787Completed16Est. Mar 2020
NCT03790839Completed15Est. Aug 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hua MedicineEmpagliflozin
Hua MedicineSitagliptin

Clinical Trials (2)

Total enrollment: 31 patients across 2 trials

NCT03790787Hua MedicineEmpagliflozin

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Start: Apr 2019Est. completion: Mar 202016 patients
Phase 1Completed
NCT03790839Hua MedicineSitagliptin

Drug Interaction Study Between Dorzagliatin and Sitagliptin

Start: Jan 2019Est. completion: Aug 201915 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space